Dr. Jenkins served as the Director of the Office of New Drugs (OND) at U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) from 2002 to 2017, where he was responsible for more than 1,000 agency employees and 19 product review divisions. During that time, he oversaw the review of thousands of new drug applications and biological licensing applications, as well as the approval of more than 400 new molecular entities. Dr. Jenkins also served as a member of the CDER Senior Leadership Team and was involved in broad policy initiatives, including negotiation and implementation of the Prescription Drug User Fee and biosimilar programs.
Dr. Jenkins began his FDA career in 1992 as a medical officer in the Division of Oncology and Pulmonary Drug Products. He subsequently served as Pulmonary Medical Group Leader and Acting Division Director before being appointed as Director of the Division of Pulmonary Drug Products in 1995. He became the Director of the Office of Drug Evaluation II in 1999 and remained in that position until he was appointed Director of OND in 2002. Following his retirement from FDA after over 25 years of Federal service in January 2017, Dr. Jenkins joined Greenleaf Health, an FDA-focused, strategic consulting firm where he serves as Principal, Drug and Biological Products.
Dr. Jenkins is board certified in internal medicine and pulmonary diseases by the American Board of Internal Medicine. He received his medical degree from the University of Tennessee, Memphis and completed his post-graduate medical training in internal medicine, pulmonary diseases, and critical care medicine at Virginia Commonwealth University/Medical College of Virginia in Richmond. Prior to joining FDA, Dr. Jenkins served as an Assistant Professor of Pulmonary and Critical Care Medicine at VCU/MCV and as a Staff Physician at the Hunter Holmes McGuire VA Medical Center in Richmond, Virginia.
What is John Kenneth Jenkins' net worth?
The estimated net worth of John Kenneth Jenkins is at least $35.53 thousand as of June 10th, 2026. Dr. Jenkins owns 3,833 shares of Corbus Pharmaceuticals stock worth more than $35,532 as of July 24th. This net worth evaluation does not reflect any other assets that Dr. Jenkins may own. Learn More about John Kenneth Jenkins' net worth.
How do I contact John Kenneth Jenkins?
Has John Kenneth Jenkins been buying or selling shares of Corbus Pharmaceuticals?
John Kenneth Jenkins has not been actively trading shares of Corbus Pharmaceuticals within the last three months. Most recently, John Kenneth Jenkins sold 4,800 shares of the business's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $7.91, for a transaction totalling $37,968.00. Following the completion of the sale, the director now directly owns 3,833 shares of the company's stock, valued at $30,319.03. Learn More on John Kenneth Jenkins' trading history.
Who are Corbus Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Corbus Pharmaceuticals?
During the last twelve months, Corbus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 13,500 shares worth more than $101,205.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 86,641 shares worth more than $1,177,188.36. The most recent insider tranaction occured on June, 10th when Director Winston Kung sold 2,026 shares worth more than $16,025.66. Insiders at Corbus Pharmaceuticals own 3.5% of the company.
Learn More about insider trades at Corbus Pharmaceuticals. Information on this page was last updated on 6/10/2026.
